GE Capital, the financial services division of US-listed industrial conglomerate General Electric, has agreed to pay R125 crore ($23m) for a 7.69% stake in Syngene International, a research subsidiary of India-based biotechnology company Biocon.

Biocon had been preparing to float Syngene, which has annual sales of R400 crore last year, but will make an initial public offering (IPO) after GE’s investment.

Kiran Mazumdar-Shaw, chairwoman of Biocon, said the deal gave Syngene a $300m valuation and added: “GE Capital’s investment in Syngene is a validation of our research services business model, which has delivered consistent value to our partners as well as other stakeholders. This [investment] takes us closer to our commitment of taking Syngene through an IPO at the most opportune time.”

Allegro Corporate Finance Advisors and law firm Mundkur Law Partners helped Biocon on the deal.

Syngene has 1,500 scientists working in a 1 million square foot building on…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?